Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors-Reference-Cited by-同舟云学术

Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors

Published:2020-10-01 Issue:19-20 Volume:31 Page:1132-1139
ISSN:1043-0342
Container-title:Human Gene Therapy
language:en
Short-container-title:Human Gene Therapy

Author:

Bernstock Joshua D.¹,Bag Asim K.²,Fiveash John³,Kachurak Kara⁴,Elsayed Galal⁵,Chagoya Gustavo⁵,Gessler Florian⁶,Valdes Pablo A.¹,Madan-Swain Avi⁴,Whitley Richard⁷,Markert James M.⁵,Gillespie G. Yancey⁵,Johnston James M.⁵,Friedman Gregory K.⁵⁴

Affiliation:

1. Department of Neurosurgery, Brigham and Women's Hospital, Harvard University, Boston, Massachusetts, USA.

2. Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.

3. Department of Radiation Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.

4. Division of Pediatric Hematology and Oncology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA.

5. Department of Neurosurgery, University of Alabama at Birmingham, Birmingham, Alabama, USA.

6. Department for Neurosurgery, Goethe University Frankfurt, Frankfurt am Main, Germany.

7. Division of Pediatric Infectious Disease, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, Alabama, USA.

Publisher

Mary Ann Liebert Inc

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/hum.2020.101

Reference39 articles.

1. Childhood brain tumors: current management, biological insights, and future directions

2. Chronic Disease in the Childhood Cancer Survivor Study Cohort: A Review of Published Findings

3. Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children

4. Pediatric cancer gone viral. Part II: potential clinical application of oncolytic herpes simplex virus-1 in children

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. cGAS-STING pathway in systemic lupus erythematosus: biological implications and therapeutic opportunities;Immunologic Research;2024-08-03

2. An Update on the Clinical Status, Challenges, and Future Directions of Oncolytic Virotherapy for Malignant Gliomas;Current Treatment Options in Oncology;2024-06-19

3. Combination Immunotherapy with Vaccine and Oncolytic HSV Virotherapy Is Time Dependent;Molecular Cancer Therapeutics;2024-05-06

4. Elucidating cellular response to treatment with viral immunotherapies in pediatric high-grade glioma and medulloblastoma;Translational Oncology;2024-02

5. Understanding and therapeutically exploiting cGAS/STING signaling in glioblastoma;Journal of Clinical Investigation;2024-01-16